Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry
AIMS: Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation (SPAF) but little is known about the rates of or reasons for rivaroxaban discontinuations in daily care. Using data from a prospective, non-interventional oral anticoagulation (NOAC) registry, we analysed...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381834/ https://www.ncbi.nlm.nih.gov/pubmed/25694537 http://dx.doi.org/10.1093/europace/euu319 |
_version_ | 1782364519080656896 |
---|---|
author | Beyer-Westendorf, Jan Förster, Kati Ebertz, Franziska Gelbricht, Vera Schreier, Thomas Göbelt, Maria Michalski, Franziska Endig, Heike Sahin, Kurtulus Tittl, Luise Weiss, Norbert |
author_facet | Beyer-Westendorf, Jan Förster, Kati Ebertz, Franziska Gelbricht, Vera Schreier, Thomas Göbelt, Maria Michalski, Franziska Endig, Heike Sahin, Kurtulus Tittl, Luise Weiss, Norbert |
author_sort | Beyer-Westendorf, Jan |
collection | PubMed |
description | AIMS: Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation (SPAF) but little is known about the rates of or reasons for rivaroxaban discontinuations in daily care. Using data from a prospective, non-interventional oral anticoagulation (NOAC) registry, we analysed rivaroxaban treatment persistence. METHODS AND RESULTS: Persistence with rivaroxaban in SPAF was assessed in an ongoing, prospective, non-interventional registry of >2600 NOAC patients from daily care using the Kaplan–Meier time-to-first-event analysis. Reasons for and management of rivaroxaban discontinuation were assessed. Potential baseline risk factors for treatment discontinuation were evaluated using Cox regression analysis. Between October 2011 and April 2014, 1204 rivaroxaban SPAF patients were enrolled [39.3% switched from vitamin K antagonists (VKAs) and 60.7% newly treated patients]. Of these, 223 patients (18.5%) stopped rivaroxaban during follow-up (median 544 days), which translates into a discontinuation rate of 13.6 (95% CI 11.8–15.4) per 100 patient-years. Most common reasons for treatment discontinuations were bleeding complications (30% of all discontinuations), followed by other side-effects (24.2%) and diagnosis of stable sinus rhythm (9.9%). A history of chronic heart failure (HR 1.43; 95% CI 1.09–1.87; P = 0.009) or diabetes (HR 1.39; 95% CI 1.06–1.82; P = 0.018) were the only statistically significant baseline risk factors for rivaroxaban discontinuation. After discontinuation of rivaroxaban, patients received antiplatelet therapy (31.8%), VKA (24.2%), another NOAC (18.4%), heparin (9.9%), or nothing (15.7%). CONCLUSION: Our data indicate that overall persistence with rivaroxaban therapy is high, with a discontinuation rate of ∼15% in the first year of treatment and few additional discontinuations thereafter. |
format | Online Article Text |
id | pubmed-4381834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43818342015-04-03 Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry Beyer-Westendorf, Jan Förster, Kati Ebertz, Franziska Gelbricht, Vera Schreier, Thomas Göbelt, Maria Michalski, Franziska Endig, Heike Sahin, Kurtulus Tittl, Luise Weiss, Norbert Europace Clinical Research AIMS: Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation (SPAF) but little is known about the rates of or reasons for rivaroxaban discontinuations in daily care. Using data from a prospective, non-interventional oral anticoagulation (NOAC) registry, we analysed rivaroxaban treatment persistence. METHODS AND RESULTS: Persistence with rivaroxaban in SPAF was assessed in an ongoing, prospective, non-interventional registry of >2600 NOAC patients from daily care using the Kaplan–Meier time-to-first-event analysis. Reasons for and management of rivaroxaban discontinuation were assessed. Potential baseline risk factors for treatment discontinuation were evaluated using Cox regression analysis. Between October 2011 and April 2014, 1204 rivaroxaban SPAF patients were enrolled [39.3% switched from vitamin K antagonists (VKAs) and 60.7% newly treated patients]. Of these, 223 patients (18.5%) stopped rivaroxaban during follow-up (median 544 days), which translates into a discontinuation rate of 13.6 (95% CI 11.8–15.4) per 100 patient-years. Most common reasons for treatment discontinuations were bleeding complications (30% of all discontinuations), followed by other side-effects (24.2%) and diagnosis of stable sinus rhythm (9.9%). A history of chronic heart failure (HR 1.43; 95% CI 1.09–1.87; P = 0.009) or diabetes (HR 1.39; 95% CI 1.06–1.82; P = 0.018) were the only statistically significant baseline risk factors for rivaroxaban discontinuation. After discontinuation of rivaroxaban, patients received antiplatelet therapy (31.8%), VKA (24.2%), another NOAC (18.4%), heparin (9.9%), or nothing (15.7%). CONCLUSION: Our data indicate that overall persistence with rivaroxaban therapy is high, with a discontinuation rate of ∼15% in the first year of treatment and few additional discontinuations thereafter. Oxford University Press 2015-04 2015-02-18 /pmc/articles/PMC4381834/ /pubmed/25694537 http://dx.doi.org/10.1093/europace/euu319 Text en © The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Beyer-Westendorf, Jan Förster, Kati Ebertz, Franziska Gelbricht, Vera Schreier, Thomas Göbelt, Maria Michalski, Franziska Endig, Heike Sahin, Kurtulus Tittl, Luise Weiss, Norbert Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry |
title | Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry |
title_full | Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry |
title_fullStr | Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry |
title_full_unstemmed | Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry |
title_short | Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry |
title_sort | drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the dresden non-interventional oral anticoagulation registry |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381834/ https://www.ncbi.nlm.nih.gov/pubmed/25694537 http://dx.doi.org/10.1093/europace/euu319 |
work_keys_str_mv | AT beyerwestendorfjan drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT forsterkati drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT ebertzfranziska drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT gelbrichtvera drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT schreierthomas drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT gobeltmaria drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT michalskifranziska drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT endigheike drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT sahinkurtulus drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT tittlluise drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry AT weissnorbert drugpersistencewithrivaroxabantherapyinatrialfibrillationpatientsresultsfromthedresdennoninterventionaloralanticoagulationregistry |